Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Financing Activities (2016 - 2023)

Spero Therapeutics (SPRO) has disclosed Cash from Financing Activities for 8 consecutive years, with $1000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Financing Activities fell 99.99% year-over-year to $1000.0, compared with a TTM value of $221000.0 through Dec 2024, changed 0.0%, and an annual FY2023 reading of $221000.0, up 100.75% over the prior year.
  • Cash from Financing Activities was $1000.0 for Q4 2023 at Spero Therapeutics, down from $220000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $77.2 million in Q3 2020 and bottomed at -$53.7 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $11.2 million, with a median of $5.9 million recorded in 2019.
  • The sharpest move saw Cash from Financing Activities surged 772050.0% in 2020, then crashed 32050.6% in 2022.
  • Year by year, Cash from Financing Activities stood at $5.6 million in 2019, then skyrocketed by 187.37% to $16.1 million in 2020, then surged by 212.92% to $50.3 million in 2021, then crashed by 71.84% to $14.2 million in 2022, then crashed by 99.99% to $1000.0 in 2023.
  • Business Quant data shows Cash from Financing Activities for SPRO at $1000.0 in Q4 2023, $220000.0 in Q3 2023, and $14.2 million in Q4 2022.